ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: L14

Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies

Xenofon Baraliakos1, Atul Deodhar2, Désirée van der Heijde3, Marina Magrey4, Walter Maksymowych5, Tetsuya Tomita6, Huji Xu7, Marga Oortgiesen8, Ute Massow9, Carmen Fleurinck10, Alicia M Ellis8, Tom Vaux11, Julie Shepherd-Smith11, Alexander Marten9 and Lianne S Gensler12, 1Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, 2Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, US, Richfield, OH, 5Department of Medicine, University of Alberta, Edmonton, AB, Canada, 6Graduate School of Health Science, Morinomiya University of Medical Science, Osaka City, Osaka City, Osaka, Japan, 7Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China (People's Republic), 8UCB Pharma, Morrisvile, NC, 9UCB Pharma, Monheim am Rhein, Nordrhein-Westfalen, Germany, 10UCB Pharma, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, 11UCB Pharma, Slough, United Kingdom, 12Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA

Meeting: ACR Convergence 2022

Date of first publication: October 18, 2022

Keywords: Ankylosing spondylitis (AS), clinical trial, Late-Breaking 2022, Randomized Trial, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: (L07–L17) Late-Breaking Abstract Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL‑17A. In the phase 3 BE MOBILE 1 and 2 studies, BKZ met all primary/secondary endpoints at Week (Wk)16 in patients (pts) with active non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS; also known as radiographic axSpA), respectively.1,2 Here, we present the first phase 3 results from up to Wk52 of BKZ treatment.

Methods: BE MOBILE 1 (NCT03928704; nr-axSpA) and 2 (NCT03928743; AS) were conducted in parallel and had similar designs, with a 16-wk placebo (PBO)-controlled and 36-wk maintenance period.1,2 Pts were randomized to subcutaneous BKZ 160 mg Q4W (BKZ) or to PBO then BKZ from Wk16 (PBO/BKZ). Efficacy endpoints were assessed through Wk52. Treatment-emergent adverse events (TEAEs; MedDRA v19.0) following first BKZ exposure are reported at the Wk52 data cut.

Results: 220/254 (86.6%) randomized pts with nr-axSpA and 298/332 (89.8%) with AS completed Wk52. In both studies, efficacy was sustained to Wk52 (Table). ASAS40 responses in BKZ-randomized pts increased from Wk16 (nr-axSpA: 47.7%; AS: 44.8%; non-responder imputation [NRI]) to Wk52 (nr-axSpA: 60.9%; AS: 58.4%; NRI) (Figure 1), with high levels of efficacy across both TNFi-naïve and TNFi-inadequate responder populations (Table). At Wk52, ASDAS < 2.1 was achieved by 61.6% and 57.1%, and ASDAS < 1.3 by 25.2% and 23.4%, of BKZ-randomized pts with nr-axSpA and AS, respectively (Figure 1). The Wk16 reductions from baseline in objective signs of inflammation (MRI, hs-CRP; Figure 2), and improvements in function (BASFI), and AS Quality of Life (Table), were maintained through 52 wks. Among PBO/BKZ-treated pts, efficacy at Wk52 was similar to that seen in BKZ-randomized pts (Figure 1; Table).

At the Wk52 data cut, 75.0% (183/244) of pts with nr-axSpA and 75.5% (249/330) of pts with AS had ≥1 TEAE on BKZ; the most frequent (by % pts) TEAEs by preferred term were nasopharyngitis (nr-axSpA: 12.3%; AS: 9.1%), upper respiratory tract infection (nr-axSpA: 9.4%; AS: 6.4%) and oral candidiasis (nr-axSpA: 7.4%; AS: 6.1%); few COVID-19 infections were reported (nr-axSpA: 7.0%; AS; 2.1%). Incidence (pts/100 patient years) of serious TEAEs were low (nr-axSpA: 4.4; AS: 7.1); no major adverse cardiovascular events, active tuberculosis cases, serious COVID-19 infections, or deaths were reported. Most incidences of fungal infection (nr-axSpA: 19.6; AS: 14.9; none serious or systemic) were Candida (nr-axSpA: 12.8; AS: 8.3) and mild to moderate; two pts with nr-axSpA and two with AS discontinued the study due to Candida infections. Incidence of IBD (nr-axSpA: 1.0; AS: 1.0) and uveitis (nr-axSpA: 1.5; AS: 2.4) were low.

Conclusion: Across the full axSpA disease spectrum, BKZ treatment resulted in sustained efficacy, including suppression of inflammation and improvements in function and quality of life, to Wk52. No new safety signals were observed, consistent with the safety profile established from Wk24 data.1,2

References: 1. Deodhar A. Ann Rheum Dis 2022;81:772–3; 2. van der Heijde D. Ann Rheum Dis 2022;81:12–3.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: X. Baraliakos, Novartis, Bristol Myers Squibb, Chugai, MSD, Pfizer, UCB Pharma, AbbVie, Eli Lilly, Galapagos, Gilead, Celgene; A. Deodhar, AbbVie, Bristol Myers Squibb, Celgene, GSK, Eli Lilly, Novartis, Pfizer, UCB Pharma, Amgen, Aurinia, Janssen, MoonLake; D. van der Heijde, AbbVie, Bayer, Bristol Myers Squibb, Cyxone, Eisai, Galapagos, Gilead, GSK, Janssen, Eli Lilly, Novartis, Pfizer, UCB Pharma, Imaging Rheumatology BV; M. Magrey, AbbVie, Eli Lilly, Novartis, Pfizer, UCB Pharma; W. Maksymowych, AbbVie, Celgene, Galapagos, Janssen, Eli Lilly, Novartis, Pfizer, UCB Pharma, CARE Arthritis Limited, Boehringer-Ingelheim; T. Tomita, AbbVie, Eli Lilly, Gilead, Novartis, Pfizer, Astellas, Bristol-Myers Squibb, Eisai, Janssen, Kyowa Kirin, Mitsubishi-Tanabe; H. Xu, AbbVie, Janssen, Novartis, Pfizer, UCB Pharma, Beigene, BioMap, IASO, Peking-Tsinghua Center for Life Sciences; M. Oortgiesen, UCB Pharma; U. Massow, UCB Pharma; C. Fleurinck, UCB Pharma; A. Ellis, UCB Pharma; T. Vaux, UCB Pharma; J. Shepherd-Smith, UCB Pharma; A. Marten, UCB Pharma; L. Gensler, AbbVie, Eli Lilly, Gilead, Janssen, MoonLake, Novartis, Pfizer, UCB Pharma.

To cite this abstract in AMA style:

Baraliakos X, Deodhar A, van der Heijde D, Magrey M, Maksymowych W, Tomita T, Xu H, Oortgiesen M, Massow U, Fleurinck C, Ellis A, Vaux T, Shepherd-Smith J, Marten A, Gensler L. Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/bimekizumab-maintains-improvements-in-efficacy-endpoints-and-has-a-consistent-safety-profile-through-52-weeks-in-patients-with-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis-resu/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bimekizumab-maintains-improvements-in-efficacy-endpoints-and-has-a-consistent-safety-profile-through-52-weeks-in-patients-with-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis-resu/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology